权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Preclinical Imaging Shared Facility

临床前成像共享设施

基本信息

批准号：
10362787
负责人：
Anna C. Sorace
金额：
$ 16.51万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-03-28 至 2022-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10362787
关键词：
Animal Model Animals Basic Science Bioluminescence Blood Vessels Cancer Detection Cancer Model Clinical Trials Comprehensive Cancer Center Consultations Evaluation Faculty Fluorescence Frequencies Funding Gamma Cameras Gamma Rays Goals Grant Human Image Image Analysis Magnetic Resonance Imaging Malignant Neoplasms Mass Spectrum Analysis Measurement Mission Molecular Multimodal Imaging Pathway interactions Patients Positioning Attribute Positron-Emission Tomography Pre-Clinical Model Research Research Personnel Resource Sharing Structure Technology Therapy Evaluation Tissue Procurements Tissue Sample Training Transgenic Animals Translating Translations Ultrasonography animal imaging cancer therapy clinically relevant cost effective equipment acquisition high resolution imaging human imaging imaging approach imaging modality imaging study instrument member metabolic imaging microCT microPET microPET/CT microSPECT molecular imaging novel imaging technology novel therapeutics optical imaging pre-clinical pre-clinical research preclinical imaging preclinical study programs real-time images receptor research study response single photon emission computed tomography technology development translation to humans tumor

项目摘要

IMAGING GROUP PRECLINICAL IMAGING SHARED FACILITY (PCISF) ABSTRACT The Preclinical Imaging Shared Facility (PCISF) fulfills a critical UAB-CCC priority by supporting over 50 members in five programs with preclinical imaging studies for detection of cancer and therapy evaluation. The facility provides detailed imaging evaluation of new cancer treatments, and thereby accelerates their translation to human trials. The specific aims are the following: (1) to provide state-of-the-art molecular imaging for preclinical studies in appropriate animal models, and support IND's for transition to human imaging studies; (2) to provide consultation and training to CCC members for molecular imaging in cancer models; (3) to establish methods for image analyses; (4) to maintain the instruments and keep them accurately calibrated; and (5) to develop novel imaging technologies and acquire new instruments. The facility will coordinate existing support mechanisms for imaging at UAB, and significantly expand the imaging effort with clinically relevant imaging that can be translated to humans. Imaging components include structural and metabolic imaging (MRI/MRS, high frequency ultrasonography and microCT), gamma-ray imaging (gamma camera, microSPECT/CT, microPET/CT, PET/MR), and optical imaging (bioluminescence and fluorescence). The PCISF has undertaken a multimodality imaging approach to provide a molecular understanding of cancer in animal models by integrating measurements of tumor mass (bioluminescence, ultrasound, CT, and MR), tumor specific targeting (SPECT, ultrasound, fluorescence, microPET), vascular parameters (ultrasound, MR), and specific therapy responses (ultrasound, bioluminescence, SPECT, MR, micoPET). Each imaging modality has advantages and their coordinated application is synergistic. The facility meets a critical need in evaluation of new therapies for cancer in animal models, thereby enabling translation of the new therapies to human trials. The facility will enhance the potential of other UAB-CCC shared facilities (High Resolution Imaging, Tissue Procurement, Mass Spectrometry/Proteonomics, Transgenic Animal, and Human Imaging) by providing real-time imaging of molecular pathways in the living animal, enabling precise tissue sampling and microanalyses, and facilitating translation to human studies.

成像组